Skip to main content

27-05-2020 | Multiple sclerosis | Video

EAN 2020 | Eculizumab reduces relapse in aquaporin-4 immunoglobulin G-positive NMOSD

Celia Oreja-Guevara presents phase 3 PREVENT study findings showing a reduction in relapse rates and relapse-related hospitalization for patients with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder receiving eculizumab (5:52).

Funding for independent interviews at EAN 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.